CASE SETTLED

Judge Richard Stearns issued a preliminary approval of the proposed settlement between TAP Pharmaceuticals and the class. Under the terms of the settlement, $150 million will be paid by TAP on behalf of all defendants.

Case Status
Settled
Settlement Amount
$150 Million
Case Caption
In re Lupron Marketing Sales Practices Litigation
Position
Co-Lead Counsel
Attorneys
Thomas M. Sobol
Practice Areas
Class Action
Pharmaceutical Fraud
Court
U.S. District Court for the District of Massachusetts
Case Number
01-CV-10861
Defendant(S)
TAP Pharmaceutical Products, Inc.
File Date
Related Documents

Hagens Berman prosecuted a lawsuit against TAP Pharmaceuticals Products, Inc. on behalf of a class of consumers and third-party payors who purchased the drug Lupron.

The lawsuit, comprised of many federal cases consolidated in United States District Court for the District of Massachusetts in Boston, charged that TAP Pharmaceutical Products, Inc., Abbott Laboratories (NYSE: ABT) and Takeda Pharmaceutical Company Limited (NYSE: TDCHF) conspired to fraudulently market, sell and distribute Lupron, causing consumers to pay inflated prices for the drug.

The suit contended that the companies did so by inflating the published average wholesale price of the drug, giving free samples to doctors knowing they would charge patients and insurers for them, and giving incentives to doctors so that they would prescribe Lupron instead of less costly alternatives.

CASE TIMELINE

Case Settled

Judge Richard Stearns issued a preliminary approval of the proposed settlement between TAP Pharmaceuticals and the class. Under the terms of the settlement, $150 million will be paid by TAP on behalf of all defendants. For more information, read Judge Stearns' order.

Hagens Berman purchases advertisements on search engines, social media sites and other websites. Transmission of the information contained or available through this website is not intended to create, and receipt does not constitute, an attorney-client relationship. If you seek legal advice or representation by Hagens Berman, you must first enter a formal agreement. All information contained in any transmission is confidential and Hagens Berman agrees to protect information against unauthorized use, publication or disclosure. This site is regulated by the Washington Rules of Professional Conduct.